Wyeth, Schwarz Pharma Off the Hook in Generic Reglan Liability Case

November 16, 2010
The U.S. District Court for the Middle District of Louisiana is the latest jurisdiction to rule that brand manufacturers cannot be held responsible for injuries suffered by patients taking generic versions of their drugs. The court granted summary judgment to Wyeth and Schwarz Pharma in a case involving their gastroesophageal reflux disease treatment Reglan (metoclopramide HCl). The plaintiff in the case, Robert Cooper, took a generic version of Reglan from January 1998 to July 2009 and subsequently developed the neurological disorder tardive dyskinesia, which causes uncontrollable body movements, particularly around the face.
Generic Line